Clinical Trial Update: Dual mTOR Inhibitor MLN0128 in Advanced Castration-Resistant Prostate Cancer (CRPC) Patients [Phase 2]

View source ↗

Summary

Phase 2 clinical trial of the dual mTOR inhibitor MLN0128 in advanced metastatic castration-resistant prostate cancer has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• MLN0128 (sapanisertib)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Metastatic Castration-Resistant Prostate Cancer | Phase 2 | Status: COMPLETED | Results posted: 2019-10-29